Published in Prostate on September 19, 2012
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol (2013) 1.00
Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. Arch Phys Med Rehabil (2014) 0.82
Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer. Asian J Androl (2016) 0.80
Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study. BMC Cancer (2013) 0.77
Robotic prostatectomy is associated with increased patient travel and treatment delay. Can Urol Assoc J (2016) 0.75
Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria. Prostate Int (2016) 0.75
Robotic prostatectomy and access to care: Canadian vs. U.S. experience. Can Urol Assoc J (2016) 0.75
Immediate versus delayed prostatectomy: Nationwide population-based study (.). Scand J Urol (2016) 0.75
Refining treatment for the men who need it: lessons from the PIVOT trial. Transl Androl Urol (2013) 0.75
Utilization and predictors of expectant management among elderly men with low-and intermediate-risk localized prostate cancer in U.S. urological practice. Urol Pract (2017) 0.75
Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World J Urol (2016) 0.75
Does surgical delay for radical prostatectomy affect patient pathological outcome? A retrospective analysis from a Canadian cohort. Can Urol Assoc J (2017) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys (2008) 3.22
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
Prostate cancer in men using testosterone supplementation. J Urol (2005) 2.12
Association between exercise and primary incidence of prostate cancer: does race matter? Cancer (2013) 2.07
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. Int J Urol (2011) 2.04
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys (2004) 1.86
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
The correlation between metabolic syndrome and prostatic diseases. Eur Urol (2011) 1.83
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol (2012) 1.81
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology (2002) 1.81
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol (2009) 1.72